About Mel Spigelman

Dr. Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), and a Member of its Board of Directors. Prior to being appointed President and CEO in 2009, Dr. Spigelman served for five and a half years as the Director of Research & Development at TB Alliance. He was instrumental in forging key organizational partnerships and building the pipeline of TB drug candidates. Notably, Dr. Spigelman was a leader in developing a regimen-based paradigm of TB drug development – a faster and more efficient approach, which is emerging as the gold standard within the TB drug research field.

Dr. Spigelman spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma) prior to joining TB Alliance. As Vice President of R&D at Knoll for eight years, Dr. Spigelman supervised all R&D activities from basic discovery to regulatory approval and Medical Affairs. He established global R&D processes as part of Knoll’s senior R&D management team, oversaw a marked increase in US regulatory filings and approvals, and supervised joint R&D programs with multiple other pharmaceutical companies.

Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine, Neoplastic Diseases and Preventive Medicine. Dr. Spigelman holds board certifications from the American Board of Internal Medicine, the American Board’s Subspecialty Board of Medical Oncology, and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988).

Presently, Dr. Spigelman is Co-Chair of the Working Group on New Drugs of the WHO Stop TB Partnership, and is a member of the Governing Board of the Tres Cantos Open Lab, GlaxoSmithKline.